Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPhase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Annals of Oncology, 06/26/09
Campo JMD et al. - Both every-3-weeks trabectedin regimes, 1.5 mg/m2 24 h and 1.3 mg/m2 3 h, were active and reasonably well tolerated in AOC platinum-sensitive patients. Trabectedin every-3-weeks has promising activity and deserves to be further evaluated in relapsed AOC.
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Temporal Reduction of HIV Type 1 Viral Load in Breast Milk by Single-Dose Nevirapine during Prevention of MTCT
AIDS Research and Human Retroviruses, 12/18/09
Efficacy and safety of a single intrathecal methylprednisolone bolus in chronic complex regional pain syndrome
European Journal of Pain, 12/18/09
Low levels of steroid-metabolizing hepatic enzyme activity may elevate responsiveness to steroids and may increase risk of steroid-induced osteonecrosis even with low glucocorticoid dose
Journal of Orthopaedic Science, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor